![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » NEW RIVER INITIATES PIVOTAL TRIAL OF NRP104
NEW RIVER INITIATES PIVOTAL TRIAL OF NRP104
May 23, 2006
New River Pharmaceuticals has reported that screening has begun in a pivotal Phase III clinical trial for NRP104 for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adult populations (ages 18 to 55). The outcome of this trial is anticipated to support a supplemental new drug application (sNDA), which the company hopes to file with the FDA in the second quarter of 2007.
NRP104 is the subject of a collaborative development and commercialization agreement between New River and Shire.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct